Nigel Russell

16PUBLICATIONS
116CO-AUTHORS
HaematologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursPlanning and decision making
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jul 19, 2026
Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study.

|Jul 03, 2025
Multimodal and Data-Driven Assessment of Myeloid Neoplasms Refines Classification across Disease States.

Curtis A Lachowiez, Georgios Asimomitis, Elsa Bernard

|Nov 18, 2024
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.

Nigel H Russell, Abin Thomas, Robert K Hills

|Sep 04, 2024
Risk Stratification in Older Intensively Treated Patients With AML.

Jurjen Versluis, Marlen Metzner, Ariel Wang

|Jan 12, 2024
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.

Nigel H Russell, Charlotte Wilhelm-Benartzi, Jad Othman

|Nov 28, 2023
A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.

Mhairi Copland, Cono Ariti, Ian F Thomas

Pageof 3

Frequent Collaborators

5 joint publications

Steven Knapper

5 joint publications

Sylvie Freeman

5 joint publications

Richard Dillon

4 joint publications

Robert K Hills